Skip to main content

Table 4 Association between human papillomavirus (HPV) seropositivitya and incident lung cancer, adjusted for matching variables

From: Absence of an association of human polyomavirus and papillomavirus infection with lung cancer in China: a nested case–control study

Antibody

Cases (n = 200)

Controls (n = 200)

  

Trend Testb

%

%

OR (95 % CIc)

P d

OR (95 % CIc)

P d

HPV 16

 E6

0.5

1.4

0.39 (0.04–3.79)

0.462

1.17 (0.97–1.43)

0.097

 E7

9.3

7.8

1.22 (0.60–2.47)

0.603

1.06 (0.97–1.15)

0.182

 L1

4.4

3.7

1.17 (0.43–3.21)

0.746

1.04 (0.95–1.15)

0.374

HPV 18

 E6

1.6

1.4

1.18 (0.23–5.93)

0.877

1.02 (0.93–1.13)

0.632

 E7

1.6

1.4

1.18 (0.23–5.93)

0.877

1.06 (0.93–1.21)

0.404

 L1

0.5

1.8

0.29 (0.03–2.66)

0.229

1.00 (0.91–1.11)

0.948

Other high-risk HPV

 31 L1

6.6

8.8

0.72 (0.34–1.53)

0.402

1.00 (0.92–1.09)

0.988

 33 L1

0.5

0.5

1.23 (0.08–20.03)

0.887

1.03 (0.93–1.15)

0.537

 52 L1

34.4

33.6

1.04 (0.68–1.57)

0.883

1.00 (0.90–1.11)

0.989

 58 L1

13.7

12.0

1.17 (0.65–2.10)

0.611

1.03 (0.94–1.12)

0.543

Low-risk HPV

 6 L1

45.4

38.2

1.34 (0.89–2.00)

0.167

1.03 (0.95–1.11)

0.503

 11 L1

20.2

13.8

1.58 (0.93–2.68)

0.097

1.05 (0.97–1.14)

0.229

  1. a Seropositivity defined as >400 MFI (median fluorescence intensity)
  2. b The trend tests estimate the odds ratio for a one unit increase in natural log transformed MFI, adjusted for matched variables
  3. c Nominal (uncorrected) 95 % confidence intervals
  4. d P-values are corrected for multiple comparisons using permutation tests